Nykode Therapeutics AS (OSL:NYKD)

Market Cap	561.99M
Revenue (ttm)	87.09M
Net Income (ttm)	-266.37M
Shares Out	326.55M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (58.11%)
Ex-Dividend Date	May 27, 2025

Volume	569,039
Average Volume	477,424
Open	1.718
Previous Close	1.700
Day's Range	1.692 - 1.750
52-Week Range	1.550 - 12.900
Beta	1.16
RSI	43.89
Earnings Date	Aug 27, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 136
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD